SnmrD.a.ryThe 94-kD large tumor (T) antigen specified by simian virus 40 (SV40) is sufficient to induce cell transformation. T antigen contains four H-2Db-restricted cytotoxic T lymphocyte (CTL) recognition epitopes that are targets for CTL clones Y-l, Y-2, Y-3, and Y-5. These epitopes have been mapped to T antigen amino acids 207-215 (site I), 223-231 (sites II and III), and 489-497 (site V), respectively. Antigenic site loss variant cells that had lost one or more CTL recognition epitopes were previously selected by coculturing SV40-transformed H-2D b cells with the sitespecific Db-restricted CTL dones. The genetic bases for T antigen CTL recognition epitope loss from the variant cells were identified by DNA amplification and direct sequencing of epitopecoding regions from variant cell DNAs. Cells selected for resistance to CTL done Y-1 (K-l; K-1,4,5; K-3,1) carry deleted SV40 genomes lacking site I, II, and III coding sequences. Point mutations present within the site II/III coding region of Y-2-/Y-3-resistant cell lines specify the substitution of asparagine for lysine as T antigen amino acid 228 (I(-2) or phenylalanine for tyrosine at position 230 (K-3). Point mutations identified within independently selected Y-5 resistant populations (K-5 and K-1,4,5) direct the substitution of isoleucine for asparagine at position 496 (K-5) or the substitution of phenylalanine for isoleucine at position 491 (K-1,4,5) of T antigen. Each substitution causes loss of the relevant CTL recognition epitope, apparently by compromising CTL T cell receptor recognition. These experiments identify specific amino acid changes within a transforming protein that facilitate transformed cell escape from site-specific CTL clones while allowing maintenance of cellular transformation. This experimental model system provides unique opportunities for studying mechanisms of transformed cell escape from active immunosurveillance in vivo, and for analysis of differential host immune responses to wildtype and mutant cell-transforming proteins.T umors induced by DNA viruses acquire spedfic antigens that provide targets for T lymphocyte-mediated immune responses modulating tumor cell growth in vivo and abrogating cellular transformation in vitro (1-4). Specific CTL recognition of tumor cells requires the presentation by MHC class I molecules of processed tumor antigen to the T lymphocyte antigen receptor. Tumor cell variants that escape CTL immunosurveiUance have been described (5-18). In most instances, the emergence of CTL escape variant cells is associated with the decrease or absence of MHC class I antigens required for antigen recognition by . In other cases, a complete loss of tumor antigen from the variants has been reported (6,10,(17)(18)(19).